



**Veterinary  
Medicines  
Directorate**

**United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
Surrey KT15 3LS**

**NATIONAL PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT**

**EU Pharma Ltd 370 mg/g Oral Paste for Horses  
Omeprogard 370 mg/g Oral Paste for Horses**

**Date Created: August 2024**

## **MODULE 1**

### **PRODUCT SUMMARY**

Name, strength and pharmaceutical form	EU Pharma Ltd 370 mg/g Oral Paste for Horses Omeprogard 370 mg/g Oral Paste for Horses
Applicant	EU Pharmaceuticals Ltd, 37 Geraldine Road, London, SW18 2NR
Active substance	Omeprazole
ATC Vetcode	QA02BC01
Target species	Horses
Indication for use	For treatment and prevention of gastric ulcers.

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 8 of VMRs 2013 (Schedule 1, Para 1) as amended.
Date of conclusion of the procedure	23/05/2024

#### I. SCIENTIFIC OVERVIEW

The application is for generic products with the reference product being GastroGard 370 mg/g Oral Paste which has been authorised in the UK since 2003. Bioequivalence has been established with regards to the reference product.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.<sup>1</sup> The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy<sup>2</sup> of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

#### II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

##### ***II.A. Composition***

The product contains omeprazole and the excipients ferric oxide yellow (E172), potassium sorbate, ethanolamine, cinnamon leaf oil (cassia oil), hydrogenated castor oil, calcium stearate, sodium stearate, sesame oil, propylene glycol octanoate decanoate.

The container/closure system consists of a white multidose syringe. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the absence of preservative are justified.

<sup>1</sup> SPC – Summary of product Characteristics.

<sup>2</sup> Efficacy – The production of a desired or intended result.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### ***II.B. Description of the Manufacturing Method***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### ***II.C. Control of Starting Materials***

The active substance is omeprazole, an established active substance described in a certificate of suitability. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The excipients all comply with a pharmacopoeia.

#### ***II.C.4. Substances of Biological Origin***

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### ***II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process***

Not applicable.

### ***II.E. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are those suitable for this pharmaceutical form.

### ***II.F. Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

### ***G. Other Information***

Shelf life of the veterinary medicinal product as packaged for sale: 27 months.  
Shelf life after first opening the immediate packaging: 28 days  
Do not store above 25°C. Replace cap after use.

## **III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACOTOXICOLOGICAL)**

### ***III.A Safety Documentation***

#### ***Pharmacological Studies***

Not required due to the legal basis of the application. Bioequivalence was established with regards to the reference product.

#### ***Toxicological Studies***

Not required due to the legal basis of the application.

#### ***User Safety***

A user risk assessment was provided in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

As this product may cause irritation and hypersensitivity reactions, avoid direct contact with skin and eyes.

People with known hypersensitivity to omeprazole and/or sesame should avoid contact with the veterinary medicinal product.

Personal protective equipment consisting of impervious gloves should be worn when handling the veterinary medicinal product.

Do not eat or drink when handling and administering the product.

Wash hands or any exposed skin after use.

The dosing syringe should be returned to the original packaging and suitably stored to prevent access by children.

In case of contact with eyes, wash immediately with clean running water and seek medical advice, and show the package leaflet or the label to the physician if symptoms persist.

Persons developing a reaction after contact with the product should avoid handling the product in future.

### ***Environmental Safety***

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

#### **Phase I:**

The product will be used to treat a small number of animals in a flock or herd and as such environmental exposure will be low. A Phase II ERA was not required.

### ***III.B.2 Residues documentation***

#### ***Residue Studies***

No residue depletion studies were conducted because the formulation of the product have a 'no MRL required' status.

## **IV. CLINICAL DOCUMENTATION**

### ***IV.I. Pre-Clinical Studies***

#### ***Pharmacology***

Not required due to the legal basis of the application.

#### ***Tolerance in the Target Species***

Not required due to the legal basis of the application.

### ***IV.II. Clinical Documentation***

Not required due to the legal basis of the application.

## **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the products are favourable.

## **MODULE 4**

### **POST- AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))